The authors found that severe disease, prior anti-TNF exposure, was a negative predictor of vedolizumab response, while ileocolonic disease, no prior surgery, and an uncomplicated phenotype were associated with a better response to ustekinumab in CD (Barre et al., 2018). Here, TNF is linked to glycogen storage disease VI.